High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC.
Montaudon E, El Botty R, Vacher S, Déas O, Naguez A, Chateau-Joubert S, Treguer D, de Plater L, Zemoura L, Némati F, Nicolas A, Chapelier A, Livartowski A, Cairo S, Daniel C, Brevet M, Marangoni E, Meseure D, Roman-Roman S, Bieche I, Girard N, Decaudin D.
Montaudon E, et al. Among authors: chapelier a.
Oncotarget. 2021 Apr 13;12(8):859-872. doi: 10.18632/oncotarget.27930. eCollection 2021 Apr 13.
Oncotarget. 2021.
PMID: 33889306
Free PMC article.